Akebia Therapeutics Inc (NASDAQ: AKBA) kicked off on Friday, up 7.59% from the previous trading day, before settling in for the closing price of $3.69. Over the past 52 weeks, AKBA has traded in a range of $0.80-$3.73.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -13.72% over the past five years. While this was happening, its average annual earnings per share was recorded 80.61%. With a float of $251.86 million, this company’s outstanding shares have now reached $261.64 million.
Let’s look at the performance matrix of the company that is accounted for 181 employees. In terms of profitability, gross margin is 67.77%, operating margin of -11.91%, and the pretax margin is -24.51%.
Akebia Therapeutics Inc (AKBA) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Akebia Therapeutics Inc is 4.10%, while institutional ownership is 36.53%. The most recent insider transaction that took place on Jun 04 ’25, was worth 47,069. In this transaction SVP, Chief Accounting Officer of this company sold 13,334 shares at a rate of $3.53, taking the stock ownership to the 266,914 shares. Before that another transaction happened on Mar 03 ’25, when Company’s CEO and President sold 46,409 for $1.83, making the entire transaction worth $84,928. This insider now owns 2,557,921 shares in total.
Akebia Therapeutics Inc (AKBA) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 80.61% per share during the next fiscal year.
Akebia Therapeutics Inc (NASDAQ: AKBA) Trading Performance Indicators
Take a look at Akebia Therapeutics Inc’s (AKBA) current performance indicators. Last quarter, stock had a quick ratio of 2.02. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.64.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.22, a number that is poised to hit -0.01 in the next quarter and is forecasted to reach 0.07 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc (AKBA)
Akebia Therapeutics Inc (NASDAQ: AKBA) saw its 5-day average volume 8.38 million, a positive change from its year-to-date volume of 4.1 million. As of the previous 9 days, the stock’s Stochastic %D was 94.65%. Additionally, its Average True Range was 0.19.
During the past 100 days, Akebia Therapeutics Inc’s (AKBA) raw stochastic average was set at 98.79%, which indicates a significant increase from 97.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.95% in the past 14 days, which was lower than the 95.67% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.42, while its 200-day Moving Average is $1.95. Nevertheless, the first resistance level for the watch stands at $4.09 in the near term. At $4.22, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.43. If the price goes on to break the first support level at $3.75, it is likely to go to the next support level at $3.54. Assuming the price breaks the second support level, the third support level stands at $3.41.
Akebia Therapeutics Inc (NASDAQ: AKBA) Key Stats
The company with the Market Capitalisation of 1.04 billion has total of 262,636K Shares Outstanding. Its annual sales at the moment are 160,180 K in contrast with the sum of -69,410 K annual income. Company’s last quarter sales were recorded 57,340 K and last quarter income was 6,110 K.
